About Acadia Pharmaceuticals
Acadia Pharmaceuticals is a company based in San Diego (United States) founded in 1993. It operates as a Direct-to-Consumer (D2C). Acadia Pharmaceuticals has raised $44.7 million across 10 funding rounds from investors including ABN AMRO, NIH and HHS. The company has 654 employees as of December 31, 2024. Acadia Pharmaceuticals offers products and services including NUPLAZID® and DAYBUE®. Acadia Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter San Diego, United States
- Employees 654 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acadia Pharmaceuticals Inc.
-
Annual Revenue
$957.8 M31.85as on Dec 31, 2024
-
Net Profit
$226.45 M469.47as on Dec 31, 2024
-
EBITDA
$100.16 M247.66as on Dec 31, 2024
-
Total Equity Funding
$44.7 M (USD)
in 10 rounds
-
Latest Funding Round
$300 M (USD), Post-IPO
Jan 06, 2016
-
Investors
ABN AMRO
& 7 more
-
Employee Count
654
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Acadia Pharmaceuticals
Acadia Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ACAD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Acadia Pharmaceuticals
Acadia Pharmaceuticals offers a comprehensive portfolio of products and services, including NUPLAZID® and DAYBUE®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for Parkinson’s Disease Psychosis is provided by NUPLAZID®.
Therapy for Rett Syndrome is offered through DAYBUE® product.
Unlock access to complete
Unlock access to complete
Leadership Team
61 people
Sales and Marketing
52 people
Software Development Team
27 people
Senior Team
25 people
Human Resources and Administration
21 people
Operations Team
12 people
Product Management Team
9 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Acadia Pharmaceuticals
Acadia Pharmaceuticals has successfully raised a total of $44.7M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $300 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $300.0M
-
First Round
First Round
(01 Jun 1997)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2016 | Amount | Post-IPO - Acadia Pharmaceuticals | Valuation |
investors |
|
| Dec, 2012 | Amount | Post-IPO - Acadia Pharmaceuticals | Valuation |
investors |
|
| Mar, 2012 | Amount | Grant - Acadia Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Acadia Pharmaceuticals
Acadia Pharmaceuticals has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include ABN AMRO, NIH and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Provision of financing, loans, equity, and insurance for Danish export and investment activities.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Acadia Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Acadia Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acadia Pharmaceuticals Comparisons
Competitors of Acadia Pharmaceuticals
Acadia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Drugs for CNS disorders are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acadia Pharmaceuticals
Frequently Asked Questions about Acadia Pharmaceuticals
When was Acadia Pharmaceuticals founded?
Acadia Pharmaceuticals was founded in 1993 and raised its 1st funding round 4 years after it was founded.
Where is Acadia Pharmaceuticals located?
Acadia Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Acadia Pharmaceuticals?
Stephen Davis is the current CEO of Acadia Pharmaceuticals.
Is Acadia Pharmaceuticals a funded company?
Acadia Pharmaceuticals is a funded company, having raised a total of $44.7M across 10 funding rounds to date. The company's 1st funding round was a Grant of $322K, raised on Jun 01, 1997.
How many employees does Acadia Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Acadia Pharmaceuticals is 654.
What is the annual revenue of Acadia Pharmaceuticals?
Annual revenue of Acadia Pharmaceuticals is $957.8M as on Dec 31, 2024.
What does Acadia Pharmaceuticals do?
Acadia Pharmaceuticals is dedicated to addressing significant challenges in neuroscience by developing innovative therapies for disorders with high unmet needs. Treatments for Parkinsons Disease Psychosis and Rett Syndrome are provided through FDA-approved products like NUPLAZID and DAYBUE. Research and development efforts are directed towards Prader-Willi Syndrome, Alzheimers Disease Psychosis, and other neuropsychiatric conditions. The company operates in the healthcare sector, emphasizing rare and neurological diseases with a commitment to patient support and advancing scientific breakthroughs.
Who are the top competitors of Acadia Pharmaceuticals?
Acadia Pharmaceuticals's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Biohaven Pharmaceutical.
What products or services does Acadia Pharmaceuticals offer?
Acadia Pharmaceuticals offers NUPLAZID® and DAYBUE®.
Is Acadia Pharmaceuticals publicly traded?
Yes, Acadia Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ACAD.
Who are Acadia Pharmaceuticals's investors?
Acadia Pharmaceuticals has 8 investors. Key investors include ABN AMRO, NIH, HHS, The Michael J. Fox Foundation, and NEA.
What is Acadia Pharmaceuticals's ticker symbol?
The ticker symbol of Acadia Pharmaceuticals is ACAD on NASDAQ.